The study followed nearly 17 million people, the majority of whom were in the 26-75 age range, and found that after climbing ...

Semaglutide and similar medications could be key players in bending the curve but enduring change ultimately hinges on a ...

Obesity rates in the US dropped slightly in 2023 for the first time in over a decade, with rates falling from 46% to 45.6%. A ...

Patients with type 2 diabetes who use semaglutide have more than double the risk of severe optic nerve damage than those who ...

Brownstein and his team noted that women and adults aged 66 to 75 saw the largest decreases in obesity. People living in the ...

The most-read obesity articles of 2024 mostly focused on insurance coverage of weight loss medications and costs.

A study published in The New England Journal of Medicine has demonstrated the potential of semaglutide for alleviating knee ...

Recent sales of a little-known stock, Madrigal Pharmaceuticals (NASDAQ: MDGL), could bode well for Novo Nordisk A/S (NYSE: ...

In a public health breakthrough, U.S. obesity rates have decreased for the first time in more than a decade, with new weight ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...

It’s not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisk’s diabetes ...

PeptiDream, the Japanese biopharma with a penchant for deal-making, has a new bargaining chip in its hand in the red-hot ...